A missense cystic fibrosis transmembrane conductance regulator mutation with variable phenotype

被引:19
作者
Kerem, E
NissimRafinia, M
Argaman, Z
Augarten, A
Bentur, L
Klar, A
Yahav, Y
Szeinberg, A
Hiba, O
Branski, D
Corey, M
Kerem, B
机构
[1] HEBREW UNIV JERUSALEM, DEPT GENET, IL-91904 JERUSALEM, ISRAEL
[2] CHAIM SHEBA MED CTR, DEPT PAEDIAT, CF CLIN, IL-52621 TEL HASHOMER, ISRAEL
[3] RAMBAM MED CTR, DEPT PAEDIAT, CF CLIN, HAIFA, ISRAEL
[4] BIKUR CHOLIM HOSP, DEPT PAEDIAT, JERUSALEM, ISRAEL
[5] HOSP SICK CHILDREN, RES INST, TORONTO, ON M5G 1X8, CANADA
关键词
cystic fibrosis; genotype-phenotype correlation; genetics; pancreatic function; pulmonary function; CFTR mutation;
D O I
10.1542/peds.100.3.e5
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective. Cystic fibrosis (CF) has variable clinical presentation. Disease severity is partially associated with the type of mutation. The aim of this study was to report genotype-phenotype analysis of the G85E mutation. Patients. The phenotype of 12 patients (8 were from the same extended family, and 5 of them were siblings from 2 families) carrying at least one copy of the G85E mutation was evaluated and compared with the phenotype of 40 patients carrying the two severe mutations, W1282X and/or Delta F508 (group 1), and with 20 patients carrying the splicing mutation, 3849+10kb C->T, which was found to be associated with milder disease (group 2). Results. A high phenotypic variability was found among the patients carrying the G85E mutation. This high variability was found among patients carrying the same genotype and among siblings. All the studied chromosomes carrying the G85E mutation had the 7T variant in the polythymidine tract at the branch/acceptor site in intron 8. Of the G85E patients, 25% had pancreatic sufficiency and none had meconium ileus, compared with 0% and 32%, respectively, of patients from group 1, and 80% and 0%, respectively, from group 2. Two patients carrying the G85E mutation had sweat chloride levels <60 mmol/L whereas all the others had typically elevated levels >80 mmol/L. Compared with group 2, patients carrying the G85E mutation were diagnosed at an earlier age and had higher sweat chloride levels, with mean values similar to group 1 but significantly more variable. Forced expiratory volume in 1 second (FEV1) was similar in the three groups, with no differences in the slope or in age-adjusted mean values of FEY. The levels of transcripts lacking exon 9 transcribed from the G85E allele measured in 3 patients were 55%, 49%, and 35% and their FEV1 values were 82%, 83%, and 50% predicated, respectively. Conclusions. The G85E mutation shows variable clinical presentation in all clinical parameters. This variability could be seen among patients carrying on the other chromosome the same CFTR mutation, and also among siblings. This variability is not associated with the level of exon 9 skipping. Thus, the G85E mutation cannot be classified either as a severe or as a mild mutation.
引用
收藏
页数:6
相关论文
共 50 条
  • [31] Phenylhydrazones as Correctors of a Mutant Cystic Fibrosis Transmembrane Conductance Regulator
    Nieddu, Erika
    Pollarolo, Benedetta
    Mazzei, Marco T.
    Anzaldi, Maria
    Schenone, Silvia
    Pedemonte, Nicoletta
    Galietta, Luis J. V.
    Mazzei, Mauro
    ARCHIV DER PHARMAZIE, 2016, 349 (02) : 112 - 123
  • [32] Control of epithelial Na+ conductance by the cystic fibrosis transmembrane conductance regulator
    Kunzelmann, K
    Schreiber, R
    Nitschke, R
    Mall, M
    PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY, 2000, 440 (02): : 193 - 201
  • [33] Cystic Fibrosis Transmembrane Conductance Regulator Folding Mutations Reveal Differences in Corrector Efficacy Linked to Increases in Immature Cystic Fibrosis Transmembrane Conductance Regulator Expression
    Peters, Kathryn W.
    Gong, Xiaoyan
    Frizzell, Raymond A.
    FRONTIERS IN PHYSIOLOGY, 2021, 12
  • [34] A NEW MISSENSE MUTATION-G1249E IN EXON-20 OF THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE
    GREIL, I
    WAGNER, K
    ROSENKRANZ, W
    HUMAN HEREDITY, 1994, 44 (04) : 238 - 240
  • [35] Activation of the Cystic Fibrosis Transmembrane Conductance Regulator by the Flavonoid Quercetin Potential Use as a Biomarker of ΔF508 Cystic Fibrosis Transmembrane Conductance Regulator Rescue
    Pyle, Louise C.
    Fulton, Jennifer C.
    Sloane, Peter A.
    Backer, Kyle
    Mazur, Marina
    Prasain, Jeevan
    Barnes, Stephen
    Clancy, J. P.
    Rowe, Steven M.
    AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2010, 43 (05) : 607 - 616
  • [36] Cystic fibrosis and survival to 40 years: a study of cystic fibrosis transmembrane conductance regulator function
    Simmonds, N. J.
    D'Souza, L.
    Roughton, M.
    Alton, E. W. F. W.
    Davies, J. C.
    Hodson, M. E.
    EUROPEAN RESPIRATORY JOURNAL, 2011, 37 (05) : 1076 - 1082
  • [37] Paediatric Thoracic Imaging in Cystic Fibrosis in the Era of Cystic Fibrosis Transmembrane Conductance Regulator Modulation
    O'Regan, Patrick W.
    Stevens, Niamh E.
    Logan, Niamh
    Ryan, David J.
    Maher, Michael M.
    CHILDREN-BASEL, 2024, 11 (02):
  • [38] Cystic Fibrosis Transmembrane Conductance Regulator Channel Dysfunction in Non-Cystic Fibrosis Bronchiectasis
    Bienvenu, Thierry
    Sermet-Gaudelus, Isabelle
    Burgel, Pierre-Regis
    Hubert, Dominique
    Crestani, Bruno
    Bassinet, Laurence
    Dusser, Daniel
    Fajac, Isabelle
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 181 (10) : 1078 - 1084
  • [39] Cystic Fibrosis Transmembrane Conductance Regulator-Modifying Medications: The Future of Cystic Fibrosis Treatment
    Pettit, Rebecca S.
    ANNALS OF PHARMACOTHERAPY, 2012, 46 (7-8) : 1065 - 1075
  • [40] A Developmental Role of the Cystic Fibrosis Transmembrane Conductance Regulator in Cystic Fibrosis Lung Disease Pathogenesis
    Huang, Elena N.
    Quach, Henry
    Lee, Jin-A
    Dierolf, Joshua
    Moraes, Theo J.
    Wong, Amy P.
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9